Elevated expression of coactivator-associated arginine methyltransferase 1 is associated with early hepatocarcinogenesis

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1669-1674

  Osada, Shigehiro ^a   Suzuki, Shugo ^b   Yoshimi, Chiaki ^a   Matsumoto, Miho ^a   Shirai, Tomoyuki ^b,c   Takahashi, Satoru ^b   Imagawa, Masayoshi ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c Nagoya City Rehabilitation Center   (Japan)

Author keywords

Cell proliferation; Histone methyltransferase; Tumor marker; Tumorigenesis

Indexed keywords

GLUTATHIONE TRANSFERASE; HISTONE METHYLTRANSFERASE; HORMONE RECEPTOR; LUCIFERASE; PROTEIN CARM1; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL PROLIFERATION; ENHANCER REGION; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CELL NUCLEUS; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GLUTATHIONE TRANSFERASE; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NF-E2-RELATED FACTOR 2; PROMOTER REGIONS, GENETIC; PROTEIN-ARGININE N-METHYLTRANSFERASES; RATS; RATS, INBRED F344; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84882632484     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2651     Document Type: Article

References (29)

1. Rodriguez-Paredes M and Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339, 2011.
2. Fraga MF, Ballestar E, Villar-Garea A, et al: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400, 2005.
3. Kelly TK, De Carvalho DD and Jones PA: Epigenetic modifications as therapeutic targets. Nat Biotechnol 28: 1069-1078, 2010.
4. Suzuki S, Asamoto M, Tsujimura K and Shirai T: Specific differences in gene expression profile revealed by cDNA microarray analysis of glutathione S-transferase placental form (GST-P) immunohistochemically positive rat liver foci and surrounding tissue. Carcinogenesis 25: 439-443, 2004.
5. Osada S, Naganawa A, Misonou M, et al: Altered gene expression of transcriptional regulatory factors in tumor marker-positive cells during chemically induced hepatocarcinogenesis. Toxicol Lett 167: 106-113, 2006.
6. Suzuki S, Takeshita K, Asamoto M, et al: High mobility group box associated with cell proliferation appears to play an important role in hepatocellular carcinogenesis in rats and humans. Toxicology 255: 160-170, 2009.
7. Ohta K, Ohigashi M, Naganawa A, et al: Histone acetyltransferase MOZ acts as a co-activator of Nrf2-MafK and induces tumour marker gene expression during hepatocarcinogenesis. Biochem J 402: 559-566, 2007.
8. Yura T, Hashizume H, Suzuki E, Imagawa M and Osada S: Promotion of anchorage-independent growth by cytoplasmic and nuclear histone deacetylase 9. J Health Sci 56: 581-588, 2010.
9. Hashizume H, Gomita U, Imagawa M and Osada S: Histone methyltransferase PR-Set7 and histone variant H2A.Z, induced during hepatocarcinogenesis, repress the promoter activity of the tumor marker gene and the Ras-induced colony formation activity. J Health Sci 57: 264-273, 2011.
10. Morimura S, Suzuki T, Hochi S, et al: Trans-activation of glutathione transferase P gene during chemical hepatocarcinogenesis of the rat. Proc Natl Acad Sci USA 90: 2065-2068, 1993.
11. Sakai M and Muramatsu M: Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis. Biochem Biophys Res Commun 357: 575-578, 2007.
12. Chen D, Ma H, Hong H, et al: Regulation of transcription by a protein methyltransferase. Science 284: 2174-2177, 1999.
13. Xu W, Chen H, Du K, et al: A transcriptional switch mediated by cofactor methylation. Science 294: 2507-2511, 2001.
14. Koh SS, Li H, Lee YH, Widelitz RB, Chuong CM and Stallcup MR: Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and β-catenin with two different classes of DNA-binding transcriptional activators. J Biol Chem 277: 26031-26035, 2002.
15. Covic M, Hassa PO, Saccani S, et al: Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-κB-dependent gene expression. EMBO J 24: 85-96, 2005.
16. Ma H, Baumann CT, Li H, et al: Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter. Curr Biol 11: 1981-1985, 2001.
17. Schurter BT, Koh SS, Chen D, et al: Methylation of histone H3 by coactivator-associated arginine methyltransferase 1. Biochemistry 40: 5747-5756, 2001.
18. Kuhn P, Chumanov R, Wang Y, Ge Y, Burgess RR and Xu W: Automethylation of CARM1 allows coupling of transcription and mRNA splicing. Nucleic Acids Res 39: 2717-2726, 2011.
19. Ohkura N, Takahashi M, Yaguchi H, Nagamura Y and Tsukada T: Coactivator-associated arginine methyltransferase 1, CARM1, affects pre-mRNA splicing in an isoform-specific manner. J Biol Chem 280: 28927-28935, 2005.
20. Ikeda H, Nishi S and Sakai M: Transcription factor Nrf2/MafK regulates rat placental glutathione S-transferase gene during hepatocarcinogenesis. Biochem J 380: 515-521, 2004.
21. Kim YR, Lee BK, Park RY, et al: Differential CARM1 expression in prostate and colorectal cancers. BMC Cancer 10: 197, 2010.
22. Hong H, Kao C, Jeng MH, et al: Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 101: 83-89, 2004.
23. Majumder S, Liu Y, Ford OH III, Mohler JL and Whang YE: Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate 66: 1292-1301, 2006.
24. McMahon M, Itoh K, Yamamoto M and Hayes JD: Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 278: 21592-21600, 2003.
25. Malloy MT, McIntosh DJ, Walters TS, Flores A, Goodwin JS and Arinze IJ: Trafficking of the transcription factor Nrf2 to promyelocytic leukemia-nuclear bodies: implications for degradation of NRF2 in the nucleus. J Biol Chem 288: 14569-14583, 2013.
26. Kwak J, Workman JL and Lee D: The proteasome and its regulatory roles in gene expression. Biochim Biophys Acta 1809: 88-96, 2011.
27. Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A and Yamamoto M: Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 6: 857-868, 2001.
28. Niture SK and Jaiswal AK: Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem 287: 9873-9886, 2012.
29. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS Jr: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.